Blog Posts
Partner Blog: “Indiana’s Life Sciences: How Collaboration Fuels Innovation and Patient Impact”
Pro-competitive mergers and acquisitions (M&A) have been critical to Indiana’s success by facilitating dynamic partnerships among our state’s universities, academic researchers and life sciences companies of all sizes.
Pro-Competitive Partnerships: The Engine of U.S. Life Sciences Innovations
Following a recent Trump Administration executive order, the Federal Trade Commission (FTC) and Department of Justice (DOJ) both released statements signaling a shift to a more balanced approach to mergers and acquisitions (M&A) enforcement.
General Catalyst: Pro-Competitive Partnerships Drive “Steady Drumbeat of Innovation” in the Life Sciences
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.”
Innovations Advanced by M&A: A New Therapy for Ulcerative Colitis
The acquisition of Arena Pharmaceuticals by Pfizer in 2022 enabled the development and commercialization of Velsipity (etrasimod), an innovative therapy for moderate to severe ulcerative colitis (UC).
NYU Law Review: Antitrust Overreach Risks Chilling Investment in Early-Stage Innovations
In their recent New York University Law Review article, “No Exit,” Matthew Wansley and Samuel Weinstein discuss how the Federal Trade Commission (FTC) and Department of Justice (DOJ)’s approach toward M&A is obstructing a critical exit point for innovative early-stage companies.
Deseret News Op-Ed: “To support biopharmaceutical breakthroughs in Utah, it’s time to revisit federal merger policies”
In a recent op-ed for Deseret News, Kelvyn Cullimore, CEO of PULSE Partner BioUtah, emphasizes the importance of federal policies that support pro-competitive life sciences mergers and acquisitions (M&A), in order to sustain innovation and growth in the life sciences — in Utah and across the country.
1H 2025 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
Read a round-up of recent PULSE updates and commentaries from the past several months of PULSE’s work.
Innovations Advanced by M&A: A First-in-Class Therapy for Myasthenia Gravis
The 2020 acquisition of Momenta Pharmaceuticals by Johnson & Johnson (J&J) was critical to advancing IMAAVY (nipocalimab), a first-in-class therapy for generalized myasthenia gravis (gMG).
Life Sciences M&A Provides a Critical Path for Innovation Amid Declining Biotech Funding
As small and mid-sized biotech companies are facing increasing funding pressures, life sciences mergers and acquisitions (M&A) have emerged as an increasingly important mechanism to sustain innovation and advance new therapies.
PULSE Urges FTC, DOJ To Reconsider Policies that Deter Pro-Competitive Life Sciences M&A
In comments to the Department of Justice (DOJ)’s Anticompetitive Regulations Task Force, PULSE urged DOJ and Federal Trade Commission (FTC) officials to revisit antitrust policies that are deterring pro-competitive life sciences M&A.